Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/155347
Title: | Trans-omics biomarker model improves prognostic prediction accuracy for early-stage lung adenocarcinoma |
Author: | Dong, Xuesi Zhang, Ruyang He, Jieyu Lai, Linjing Alolga, Raphael N. Shen, Sipeng Zhu, Ying You, Dongfang Lin, Lijuan Chen, Chao Zhao, Yang Duan, Weiwei Su, Li Shafer, Andrea Salama, Moran Fleischer, Thomas Bjaanæs, Maria Moksnes Karlsson, Anna Planck, Maria Wang, Rui Staaf, Johan Helland, Åslaug Esteller, Manel Wei, Yongyue Chen, Feng Christiani, David C. |
Keywords: | ADN Metilació Expressió gènica Càncer de pulmó DNA Methylation Gene expression Lung cancer |
Issue Date: | 21-Aug-2019 |
Publisher: | Impact Journals |
Abstract: | Limited studies have focused on developing prognostic models with trans-omics biomarkers for early-stage lung adenocarcinoma (LUAD). We performed integrative analysis of clinical information, DNA methylation, and gene expression data using 825 early-stage LUAD patients from 5 cohorts. Ranger algorithm was used to screen prognosis-associated biomarkers, which were confirmed with a validation phase. Clinical and biomarker information was fused using an iCluster plus algorithm, which significantly distinguished patients into high- and low-mortality risk groups (Pdiscovery = 0.01 and Pvalidation = 2.71×10-3). Further, potential functional DNA methylation-gene expression-overall survival pathways were evaluated by causal mediation analysis. The effect of DNA methylation level on LUAD survival was significantly mediated through gene expression level. By adding DNA methylation and gene expression biomarkers to a model of only clinical data, the AUCs of the trans-omics model improved by 18.3% (to 87.2%) and 16.4% (to 85.3%) in discovery and validation phases, respectively. Further, concordance index of the nomogram was 0.81 and 0.77 in discovery and validation phases, respectively. Based on systematic review of published literatures, our model was superior to all existing models for early-stage LUAD. In summary, our trans-omics model may help physicians accurately identify patients with high mortality risk. |
Note: | Reproducció del document publicat a: https://doi.org/10.18632/aging.102189 |
It is part of: | Aging, 2019, vol. 11, num. 16, p. 6312-6335 |
URI: | http://hdl.handle.net/2445/155347 |
Related resource: | https://doi.org/10.18632/aging.102189 |
ISSN: | 1945-4589 |
Appears in Collections: | Articles publicats en revistes (Ciències Fisiològiques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
695390.pdf | 4.5 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License